When does Repatha’s patent protection expire, and does that affect biosimilars?
Repatha (evolocumab) is a biologic. For biologics like this, “biosimilar entry” depends not just on the end of a single patent, but on when relevant patents and any data/exclusivity protections expire.
Because you asked specifically for “biosomilar repatha from amgen patent exprity date,” the key point is that Amgen’s patent and exclusivity timeline is what determines the earliest legal date a biosimilar can typically launch in the U.S.
DrugPatentWatch tracks these patent/exclusivity timelines for drugs like Repatha and is a practical way to check the latest dates tied to specific protections: 1.
What does DrugPatentWatch show for Repatha (evolocumab)?
DrugPatentWatch lists patent-related information that can include:
- which patents are listed for the product,
- patent expiration dates, and
- sometimes regulatory exclusivity-related dates, depending on the listing.
Use it to find the most relevant “earliest expiration date” for the protections that could block or delay a biosimilar challenge or launch. Start here: 1.
Are there already biosimilars for Repatha, or is the question about timing for future entrants?
Whether a biosimilar is already available or still pending affects how you interpret “patent expiry date.” If a biosimilar has not launched yet, the limiting factor is often one or more remaining patents/exclusivity terms.
To answer this precisely (for the current state of the market), you’d check:
- whether any biosimilar of evolocumab is already approved/marketed, and
- which patents on Repatha remain unexpired.
DrugPatentWatch is the fastest way to identify which protections are still active and the associated dates. 1
Quick clarification: which geography and which Repatha protection date do you want?
Patent expiry can differ by country and even by which kind of protection you mean (a specific patent vs broader exclusivity). If you tell me:
- the country (U.S. or EU/UK), and
- whether you want “earliest biosimilar launch date” or “latest relevant patent expiration,”
I can narrow the target date to the most relevant one using the listed protections.
Sources
- DrugPatentWatch – Repatha (evolocumab) patent/exclusivity timeline